These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 8329837

  • 1. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM, Carmel R, Pattamakom S, Challita PM, Rabinowitz AP, Pattengale PK.
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of human natural killer cell activity by platelet-derived growth factor. II. Membrane binding studies, effects of recombinant IFN-alpha and IL-2, and lack of effect on T cell and antibody-dependent cellular cytotoxicity.
    Gersuk GM, Chang WC, Pattengale PK.
    J Immunol; 1988 Dec 01; 141(11):4031-8. PubMed ID: 2846698
    [Abstract] [Full Text] [Related]

  • 3. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC, Hsiao MH, Pattengale PK.
    Nat Immun Cell Growth Regul; 1991 Dec 01; 10(2):57-70. PubMed ID: 1881400
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of human natural killer cell activity by platelet-derived growth factor.
    Gersuk GM, Holloway JM, Chang WC, Pattengale PK.
    Nat Immun Cell Growth Regul; 1986 Dec 01; 5(6):283-93. PubMed ID: 3796638
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2.
    Bonavida B, Katz J, Gottlieb M.
    J Immunol; 1986 Aug 15; 137(4):1157-63. PubMed ID: 3488345
    [Abstract] [Full Text] [Related]

  • 6. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC, Chang TH, Goldberg A, Novetsky AD, Lichter S, Lipton J.
    Exp Hematol; 2006 Dec 15; 34(12):1617-23. PubMed ID: 17157157
    [Abstract] [Full Text] [Related]

  • 7. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
    Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM, Jensen MK.
    Eur J Haematol; 2015 Mar 15; 94(3):227-34. PubMed ID: 25082025
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 15; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders.
    Ferrero D, Tarella C, Pregno P, Pileri A, Gallo E.
    Cancer Res; 1986 Feb 15; 46(2):975-80. PubMed ID: 3455679
    [Abstract] [Full Text] [Related]

  • 15. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
    Gaddy J, Broxmeyer HE.
    Cell Immunol; 1997 Sep 15; 180(2):132-42. PubMed ID: 9341743
    [Abstract] [Full Text] [Related]

  • 16. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
    Passamonti F, Vanelli L, Malabarba L, Rumi E, Pungolino E, Malcovati L, Pascutto C, Morra E, Lazzarino M, Cazzola M.
    Haematologica; 2003 Oct 15; 88(10):1123-9. PubMed ID: 14555308
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus.
    Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, Shin MH, Park JJ, Kim TJ, Lee SS, Yoo DH, Kang HS.
    Arthritis Rheum; 2009 Jun 15; 60(6):1753-63. PubMed ID: 19479851
    [Abstract] [Full Text] [Related]

  • 19. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec 15; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF). III. Membrane binding studies and differential biological effect of recombinant PDGF isoforms.
    Gersuk GM, Westermark B, Mohabeer AJ, Challita PM, Pattamakom S, Pattengale PK.
    Scand J Immunol; 1991 May 15; 33(5):521-32. PubMed ID: 1851574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.